In this review, we summarize the pieces of evidence showing that PACAP and VIP administration help to preserve cognitive function in different preclinical models of Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). This evidence concerns the gene ADCYAP1 and Parkinson disease.